Table 1.
Clinical characteristics of the 368 patients with diffuse large B-cell lymphoma (DLBCL) (the training set) with wild-type (WT) or mutated MYC
| Variables | MUT-Myc | WT-Myc | P | MUT-3'UTR | WT-3'UTR | P | MUT-5'UTR | WT-5'UTR | P |
|---|---|---|---|---|---|---|---|---|---|
| Age | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |||
| < 60 y | 27 (52.9) | 129 (40.7) | 0.13 | 7 (35) | 149 (42.8) | 0.49 | 30 (43.5) | 126 (42.1) | 0.84 |
| ≥ 60 y | 24 (47.1) | 188 (59.3) | 13 (65) | 199 (57.2) | 39 (56.5) | 173 (57.9) | |||
| Sex | |||||||||
| Female | 18 (35.3) | 137 (43.2) | 0.29 | 4 (20) | 151 (43.4) | 0.039 | 25 (36.2) | 130 (43.5) | 0.28 |
| Male | 33 (64.7) | 180 (56.8) | 16 (80) | 197 (56.6) | 44 (63.8) | 169 (56.5) | |||
| Stage | |||||||||
| I - II | 21 (41.2) | 135 (44.4) | 0.67 | 10 (52.6) | 146 (43.5) | 0.43 | 31 (45.6) | 125 (43.6) | 0.76 |
| III - IV | 30 (58.8) | 169 (55.6) | 9 (47.4) | 190 (56.5) | 37 (54.4) | 162 (56.4) | |||
| B-symptoms | |||||||||
| No | 31 (63.3) | 193 (64.8) | 0.84 | 13 (68.4) | 211 (64.3) | 0.72 | 42 (63.6) | 182 (64.8) | 0.86 |
| Yes | 18 (36.7) | 105 (35.2) | 6 (31.6) | 117 (35.7) | 24 (36.4) | 99 (35.2) | |||
| LDH level | |||||||||
| Normal | 20 (41.7) | 117 (40.9) | 0.92 | 9 (47.4) | 128 (40.6) | 0.56 | 32 (50.8) | 105 (38.7) | 0.08 |
| Elevated | 28 (58.3) | 169 (59.1) | 10 (52.6) | 187 (59.4) | 31 (49.2) | 166 (61.3) | |||
| No. of extranodal sites | |||||||||
| 0 – 1 | 38 (76.0) | 227 (75.9) | 0.99 | 17 (89.5) | 248 (75.2) | 0.16 | 50 (78.1) | 215 (75.4) | 0.65 |
| ≥ 2 | 12 (24.0) | 72 (24.1) | 2 (10.5) | 82 (24.8) | 14 (21.9) | 70 (24.6) | |||
| ECOG performance status | |||||||||
| 0 – 1 | 39 (83.0) | 230 (82.1) | 0.89 | 17 (89.5) | 252 (81.8) | 0.40 | 49 (83.1) | 220 (82.1) | 0.86 |
| ≥ 2 | 8 (17.0) | 50 (17.9) | 2 (10.5) | 56 (18.2) | 10 (16.9) | 48 (17.9) | |||
| Size of largest tumor | |||||||||
| < 5cm | 21 (60.0) | 146 (59.8) | 0.98 | 9 (64.3) | 158 (59.6) | 0.73 | 28 (54.9) | 139 (61) | 0.42 |
| ≥ 5cm | 14 (40.0) | 98 (40.2) | 5 (35.7) | 107 (40.4) | 23 (45.1) | 89 (39) | |||
| IPI score | |||||||||
| 0 – 2 | 32 (64.0) | 184 (60.5) | 0.64 | 14 (73.7) | 202 (60.3) | 0.24 | 41 (61.2) | 175 (61) | 0.97 |
| 3 – 5 | 18 (36.0) | 120 (39.5) | 5 (26.3) | 133 (39.7) | 26 (38.8) | 112 (39) | |||
| Therapy response | |||||||||
| CR | 36 (70.6) | 235 (74.1) | 0.59 | 16 (80) | 255 (73.3) | 0.50 | 49 (63.6) | 231 (77.3) | 0.015 |
| PR | 6 | 47 | 2 | 51 | 13 | 40 | |||
| SD | 0 | 16 | 0 | 16 | 0 | 14 | |||
| PD | 9 | 19 | 2 | 26 | 15 | 14 | |||
| Primary origin | |||||||||
| Nodal | 39 (76.5) | 193 (62.5) | 0.05 | 11 (55) | 221 (35.0) | 0.40 | 42 (61.8) | 190 (65.1) | 0.61 |
| Extranodal | 12 (23.5) | 116 (37.5) | 9 (45) | 119 (65.5) | 26 (38.2) | 102 (34.9) | |||
| Cell-of-origin | |||||||||
| GCB | 30 (58.8) | 159 (50.5) | 0.29 | 11 (55) | 178 (51.4) | 0.82 | 41 (59.4) | 148 (49.8) | 0.18 |
| ABC | 21 (41.2) | 156 (49.5) | 9 (45) | 168 (48.6) | 28 (40.6) | 149 (50.2) | |||
Abbreviations: LDH, lactate dehydrogenase; ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; CR, complete remission; PR, partial response; SD, stable disease; PD, progressive disease; GCB, germinal center B-cell–like; ABC, activated B-cell–like. For therapy response, we calculated P values as CR versus other responses. Some data for certain cases were not available.